Hypoalbuminemia

Definition

Causes

1. Decreased Hepatic Synthesis

• Liver disease (cirrhosis, hepatitis, hepatic failure) - most common chronic cause
• Malnutrition / protein-energy undernutrition - inadequate amino acid substrate
• Acute-phase response / inflammation - IL-6 and TNF suppress albumin mRNA transcription (albumin is a negative acute-phase reactant)
• Malabsorption syndromes - celiac disease, Crohn's disease, short bowel syndrome

2. Increased Losses

• Nephrotic syndrome - urinary albumin loss > 3.5 g/day; albumin accounts for > 80% of excreted proteins
• Protein-losing enteropathy - IBD, intestinal lymphangiectasia, Menetrier's disease
• Burns / exfoliative skin disease - transdermal protein losses
• Large-volume hemorrhage or drainage (ascitic tap, pleural drainage)

3. Increased Catabolism / Distribution

• Sepsis / critical illness - capillary leak moves albumin into the interstitial space (third-spacing); increased catabolism
• Post-surgical state - rapid post-operative falls are almost always due to redistribution/capillary leak, not decreased synthesis
• Hyperthyroidism

4. Dilutional

• Fluid overload / aggressive IV hydration
• SIADH
• Pregnancy (physiological, due to expanded plasma volume)

Pathogenesis in Nephrotic Syndrome (Best Studied Model)

1. Urinary albumin loss - the direct driver, but not sufficient alone
2. Inadequate hepatic synthetic response - though the liver CAN increase albumin synthesis up to 300%, in nephrotic patients this response is blunted; the hepatic interstitial albumin pool remains relatively normal, so the liver does not "sense" the degree of systemic depletion
3. Increased tubular catabolism - a high-capacity, low-affinity tubular transport system allows increased reabsorption and catabolism of filtered albumin as the filtered load rises
4. Malnutrition - low dietary protein further impairs hepatic albumin mRNA expression and synthesis

• Brenner and Rector's The Kidney, p. 1313-1315
• Comprehensive Clinical Nephrology 7e, p. 240

Consequences and Clinical Effects

Edema Formation

• Underfill: Low oncotic pressure → decreased circulating volume → RAAS activation → aldosterone-driven sodium retention → worsening edema
• Overfill (more common): Primary ENaC activation in the distal nephron by proteolytic enzymes → sodium/water retention → increased blood volume + low oncotic pressure → transudation

Renal Function

• Impaired sodium and fluid homeostasis
• Reduced GFR: in minimal change and membranous nephropathy, this is due to lowered glomerular hydraulic permeability from podocyte foot process effacement; the fall in GFR is partially offset by elevated net ultrafiltration pressure from reduced intraglomerular oncotic pressure

Hypocalcemia

• Total calcium is low because ~50% is protein-bound; ionized calcium is usually normal
• However, some nephrotic patients have true hypocalcemia due to urinary loss of vitamin D-binding protein → vitamin D deficiency → secondary hyperparathyroidism
• Formula: corrected Ca²⁺ = measured Ca + 0.8 × (4.0 - albumin in g/dL)

Hypercoagulability

• Loss of anticoagulant proteins (antithrombin III, protein C, protein S) in urine
• Elevated fibrinogen and clotting factors (large molecules retained) → net prothrombotic state
• Increased risk of DVT, PE, renal vein thrombosis

Hyperlipidemia

• Reduced oncotic pressure stimulates non-discriminatory hepatic protein synthesis → increased VLDL and LDL production
• Reduced lipoprotein lipase activity (loss of enzyme cofactors in urine)

Drug Pharmacokinetics

• Fewer binding sites → increased free drug fraction → enhanced pharmacological (and toxic) effects at standard doses
• Especially affects highly protein-bound drugs: phenytoin, warfarin, valproate, furosemide, NSAIDs, salicylates
• At steady state, faster drug metabolism partially compensates, but caution is still required
• Etomidate: decreased protein binding in hypoalbuminemia enhances its pharmacological effects
• Goldman-Cecil Medicine, p. 1071; Morgan & Mikhail's Clinical Anesthesiology 7e

Negative Nitrogen Balance / Muscle Wasting

• Heavy proteinuria causes marked negative nitrogen balance
• Loss of 10-20% lean body mass can occur in nephrotic syndrome, often masked by edema
• Albumin turnover is increased due to tubular catabolism of filtered protein

Impaired Immune Function

• Loss of immunoglobulins and complement factors in urine (in nephrotic syndrome)
• Increased susceptibility to infections, especially encapsulated organisms (Streptococcus pneumoniae)

Wound Healing / Surgical Risk

• Post-surgical hypoalbuminemia is an ominous prognostic finding
• Associated with poor wound healing, pressure ulcers, and increased morbidity
• Albumin infusions do not improve survival; the priority is nutritional support, skin integrity, minimizing diuretics

Clinical Signs

Investigations

• Serum albumin (direct measurement)
• 24-hour urine protein or spot urine protein:creatinine ratio (nephrotic syndrome)
• LFTs / synthetic function (PT, INR, bilirubin) - liver disease
• Stool alpha-1 antitrypsin - protein-losing enteropathy
• CRP / ESR - inflammatory/acute-phase state
• Lipid profile, coagulation studies (antithrombin III)
• Serum calcium (corrected), vitamin D levels
• CBC, albumin-to-creatinine ratio

Management

• Adult: 25 g IV over 30-120 min; repeat every 1-2 days PRN (max 2 g/kg/24h)
• Child: 0.5-1 g/kg/dose IV over 30-120 min; repeat every 1-2 days PRN
• Hypovolemia: 0.5-1 g/kg IV rapid infusion; may repeat after 15-30 min
• Contraindicated in CHF or severe anemia; can cause fluid overload
• Important caveat: albumin infusions do not correct the underlying metabolic abnormality and have NOT been shown to improve survival in surgical/critically ill patients; they are best used for specific indications (spontaneous bacterial peritonitis, large-volume paracentesis, hepatorenal syndrome)
• Harriet Lane Handbook 23e, p. 1001

Recent Evidence

Dopamine Signalling - Phasic ("Abrupt") vs Tonic Modes

Note on terminology: "Abrupt dopamine signalling" is not a standard single term in neuroscience. Based on the context, this most likely refers to phasic dopamine signalling - the abrupt, burst-mode firing of dopamine neurons that encodes reward, salience, and prediction error. The full picture of dopamine signalling is covered below, with phasic signalling as the central focus.

1. Dopamine - Overview

• Kaplan & Sadock's Comprehensive Textbook of Psychiatry

2. Synthesis and Life Cycle of Dopamine

1. Tyrosine (from dietary protein/phenylalanine) enters neurons via LNAA transporter
2. Tyrosine → L-DOPA via tyrosine hydroxylase (TH) - the rate-limiting step; requires tetrahydrobiopterin cofactor
3. L-DOPA → Dopamine via aromatic amino acid decarboxylase (AADC) in the cytosol
4. Dopamine is packaged into vesicles by VMAT-2 (vesicular monoamine transporter-2), protecting it from cytoplasmic MAO degradation

• Reuptake via the dopamine transporter (DAT) - the primary mechanism
• MAO (monoamine oxidase) degrades cytoplasmic dopamine → DOPAC
• COMT (catechol-O-methyltransferase) in the synapse/postsynaptic cell → HVA (homovanillic acid)

3. Tonic vs Phasic Dopamine Signalling

Tonic (Baseline) Mode

• Slow, pacemaker-like spontaneous firing (~2-5 Hz)
• Maintains a low, steady baseline of extracellular dopamine
• Preferentially activates high-affinity D3 receptors first, then D2, and last D1
• Functions: sets the background "tone" for motor function, motivation, cognition
• Loss of tonic DA is the basis of Parkinson disease and can be restored by L-DOPA

Phasic ("Abrupt") Mode - The Central Concept

• Burst firing of dopamine neurons - short, rapid volleys (~100 ms duration, ~100 ms latency from stimulus)
• Releases a flurry of dopamine that recruits all three DA receptor subtypes (D1, D2, D3)
• Triggered by: unexpected reward, novel stimuli, salient sensory events, or stimuli that predict reward
• Encodes the reward prediction error (RPE) signal:
  • Reward better than predicted → phasic DA burst (positive RPE)
  • Reward as predicted → no change in DA firing
  • Expected reward omitted → transient dopamine neuron pause (negative RPE)

"The phasic activity of midbrain dopaminergic neurons provides a teaching signal for reinforcement learning." - Kandel's Principles of Neural Science, 6th ed.

• Tonic and phasic modes operate as a continuum: the post-burst elevation in extracellular DA can sustain tonic DA function, linking the two modes
• Stahl's Essential Psychopharmacology; Kaplan & Sadock's Comprehensive Textbook of Psychiatry

4. Major Dopamine Pathways

5. Phasic DA in the Basal Ganglia - Reinforcement Learning

1. A behavior is initiated, leaving an "eligibility trace" in recently active striatal neurons
2. If the behavior leads to unexpected reward, a phasic DA burst is broadcast widely
3. Only neurons carrying the eligibility trace are potentiated (by simultaneous phasic DA + glutamate)
4. This strengthens the direct pathway (D1-expressing neurons → "Go" signal) for that behavior
5. Future action selection is biased toward reward-predicting options

• Habit formation
• Drug addiction (drugs of abuse hijack phasic DA signaling - see below)
• Kandel's Principles of Neural Science, 6th ed., p. 992-993

6. Phasic DA and Addiction

"The time course of dopamine signalling is a key factor. Rapid phasic dopamine neuronal firing encodes the reward experience and value and is necessary to learn the association of stimuli with reward." - Kaplan & Sadock's

• Drugs of abuse (cocaine, amphetamine, opioids) produce abnormally large, rapid phasic DA surges in the nucleus accumbens
• This overwhelms normal reward circuitry, creating pathologically strong associations (conditioned cues)
• Cocaine blocks DAT → prolongs DA in the synapse
• Amphetamine reverses VMAT-2 and DAT → floods the synapse with DA (non-exocytotic release)
• The rate of DA rise matters: fast IV/smoked administration = greater abuse potential than slow oral routes
• Immediate-release stimulants (methylphenidate, amphetamine) amplify both tonic AND phasic DA signals; their abuse potential is linked to this phasic amplification - Stahl's Essential Psychopharmacology

7. Phasic DA in ADHD

• Low tonic DA → inadequate D1 stimulation → impaired working memory and attention
• Impaired phasic DA → poor reward-based learning and motivation

8. Receptor-Level Signal Transduction (Intracellular)

9. Pharmacological Targets

10. Clinical Disorders Involving Abnormal DA Signalling

Restless Legs Syndrome (RLS) / Willis-Ekbom Disease

Definition & Overview

Diagnostic Criteria (IRLSSG 2014)

Supportive (Non-Essential) Features

• Positive family history (3-5x higher prevalence in first-degree relatives)
• Response to dopaminergic therapy
• Periodic limb movements during sleep (PLMS) - present in ~80-90% of patients
• Sleep disturbance (sleep-onset insomnia, daytime sleepiness)
• Normal examination in the primary/idiopathic form

Note: DSM-5 additionally requires frequency ≥3 times/week and duration ≥3 months. AASM requires a clinical significance specifier.

• Kaplan & Sadock's Comprehensive Textbook of Psychiatry; Bradley and Daroff's Neurology in Clinical Practice

Sensory Descriptions

• Creeping, crawling, tingling
• Burning, aching, cramping
• Itching, "internal itch"
• Knife-like, heaviness, tension
• "Worms under the skin," coldness

"Patients may report that the discomfort can be torturously debilitating and cause them to walk or continuously move their legs until the early morning hours." - Goldman-Cecil Medicine

Pathophysiology

Central Iron-Dopamine Hypothesis

• Iron deficiency in the CNS (even with normal serum hemoglobin/hematocrit) → reduced activity of tyrosine hydroxylase (iron is a cofactor) → decreased dopamine synthesis
• Reduced dopaminergic modulation of spinal cord excitability → sensory overactivity and motor restlessness
• PET/SPECT studies show reduced dopamine receptor and transporter binding in the basal ganglia
• Serum ferritin is often low in RLS patients, even when other iron indices are normal - the most clinically useful screening test

Genetics

• MEIS1, BTBD9, MAP2K5/LBXCOR1, PTPRD, PCDHA3
• Loci on chromosomes 2p14, 16q12.1, 12q, 14q, 9p, 2q, 20p
• ~40-50% prevalence in first-degree relatives of idiopathic cases; 83% concordance in monozygotic twins
• Goldman-Cecil Medicine; Bradley and Daroff's Neurology

Secondary Causes

Associated Condition: Periodic Limb Movements of Sleep (PLMS)

• Present in ~80-90% of RLS patients (but only a minority of PLMS patients have RLS)
• Repetitive movements every 20-90 seconds for minutes to an hour
• Primarily involve the tibialis anterior - dorsiflexion of foot and big toe, sometimes triple flexion of hip and knee (similar to Babinski response)
• Duration 1-2 seconds (slower than myoclonus)
• Causes microarousals or full arousals; patient is usually unaware - told by bed partner or suspects from disarray of bedclothes
• Diagnosis requires polysomnography (unlike RLS which is diagnosed clinically)

Investigation

• Serum ferritin - the only recommended routine test; check for iron deficiency
  • Treat if ferritin < 75 µg/L (some guidelines use lower cutoffs)
• Serum iron, TIBC, CBC - assess iron stores and anemia
• Polysomnography - if PLMS suspected, sleep apnea co-exists, or diagnosis is uncertain
• Renal function (creatinine, eGFR) - rule out uremia
• Thyroid function tests if clinically indicated
• No neuroimaging required for typical primary RLS

Management

Step 1: Treat Secondary Causes First

• Iron replacement if ferritin < 75 µg/L: Ferrous sulfate 325 mg BID-TID (note GI side effects)
• Ferrous sulfate + vitamin C enhances absorption
• Correct uremia, discontinue offending drugs, treat underlying neuropathy

Step 2: Non-Pharmacological Measures

• Good sleep hygiene
• Avoid caffeine, alcohol, sleep deprivation
• Regular moderate exercise; leg stretching
• Hot baths or massage before bed
• Early mobilization post-surgery (best strategy in post-op patients)
• Mental engagement (video games, puzzles) while sedentary

Step 3: Pharmacological Treatment

Current First-Line: Alpha-2-Delta (α₂δ) Ligands

Dopamine Agonists (Use Cautiously - Augmentation Risk)

Augmentation: A paradoxical worsening where symptoms appear earlier in the day, spread to other body parts, and intensify - the major limitation of dopaminergic therapy. Risk is higher with levodopa > dopamine agonists. If augmentation occurs, carefully withdraw the dopaminergic agent and switch to α₂δ ligand.

Levodopa (Not for Chronic Use)

• Levodopa/carbidopa 25/100 mg, ½-3 tabs 30 min before bedtime
• Effective short-term; significant augmentation risk with chronic use
• Best reserved for intermittent, "on-demand" use

Second/Third-Line Agents

Medication Selection Guide (IRLSSG-Adapted)

Intravenous Iron

• IV iron (e.g., ferric carboxymaltose, low-molecular-weight iron dextran) can be highly effective especially if oral iron is not tolerated or ferritin remains low
• Effective even in patients without frank iron-deficiency anemia

Differential Diagnosis

Recent Evidence (2025 AASM Guidelines)

• Dopamine agonists are no longer unconditionally first-line - α₂δ ligands are now preferred in many clinical scenarios given augmentation risk
• Strong evidence supports gabapentin enacarbil and pregabalin
• IV iron is increasingly recognized as an effective disease-modifying intervention
• A 2024 systematic review (PMID: 39064758) assessed dietary supplementation (especially iron, magnesium, vitamin D) with modest supportive evidence